Automate Your Wheel Strategy on KRYS
With Tiblio's Option Bot, you can configure your own wheel strategy including KRYS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KRYS
- Rev/Share 11.572
- Book/Share 34.1723
- PB 3.7004
- Debt/Equity 0.0098
- CurrentRatio 9.6466
- ROIC 0.1091
- MktCap 3654240615.0
- FreeCF/Share 4.4879
- PFCF 28.2576
- PE 29.3938
- Debt/Assets 0.009
- DivYield 0
- ROE 0.1356
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | KRYS | Jefferies | -- | Buy | -- | $245 | March 5, 2025 |
News
Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Krystal Biotech, Inc. (NASDAQ:KRYS ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Stephane Paquette - VP, Corporate Development Krish Krishnan - Chairman and CEO Suma Krishnan - President, Research and Development Jennifer McDonough - SVP, Patient Access, Analytics and Operations Christine Wilson - SVP and Head, U.S. Sales and Marketing Kate Romano - CAO Conference Call Participants Alec Stranahan - Bank of America Roger Song - Jefferies Ritu Baral - TD Cowen Gavin Clark-Gartner - Evercore ISI Sami Corwin - William Blair Andrea Newkirk - Goldman Sachs Debjit Chattopadhyay - Guggenheim Securities Yigal Nochomovitz …
Read More
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
KRYS reports disappointing first-quarter 2025 results, with both earnings and sales missing estimates. Shares down.
Read More
Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.20 per share, missing the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $0.03 per share a year ago.
Read More
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional PITTSBURGH, April 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that on April 23, 2025, the European Commission (EC) granted marketing authorization to VYJUVEK® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. VYJUVEK is designed to …
Read More
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
Read More
Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK
Published: March 24, 2025 by: Seeking Alpha
Sentiment: Positive
Krystal Biotech's VYJUVEK, a first-mover gene therapy for DEB, has received a positive CHMP recommendation, potentially boosting its global market presence and valuation. Despite KRYS's premium valuation, its growth potential, strong financials, and first-mover advantage justify the market's appraisal, with a fair value estimate of $175-$185 per share. Key risks include regulatory setbacks, reimbursement issues, competition from Abeona's EB-101, and high operational expenses, which could impact short-term valuation and cash flow.
Read More
Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Read More
Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.
Read More
Why Krystal Biotech (KRYS) Might be Well Poised for a Surge
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Why Krystal Biotech, Inc. (KRYS) is a Top Momentum Stock for the Long-Term
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Krystal Biotech (KRYS) Upgraded to Buy: Here's What You Should Know
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Krystal Biotech (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus
Published: February 21, 2025 by: Seeking Alpha
Sentiment: Positive
Krystal Biotech's VYJUVEK shows strong growth, with 2025 sales expected to exceed $1B, bolstered by launches in the EU and Japan. Q4 earnings beat EPS expectations but slightly missed revenue forecasts; however, management's 2025 outlook coming catalysts drove a strong rally in shares. Key 2025 catalysts include VYJUVEK's EU and Japan launches, Phase 3 ocular DEB results, and progress in CF and lung gene therapy.
Read More
Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
KRYS stock gains despite reporting mixed fourth-quarter results as lead drug Vyjuvek's launch in the United States shows strong uptake.
Read More
Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Krystal Biotech, Inc. (NASDAQ:KRYS ) Q4 2024 Results Conference Call February 19, 2025 8:30 AM ET Company Participants Stephane Paquette - VP, Corporate Development Krish Krishnan - Chairman and CEO Jennifer McDonough - SVP, Patient Access, Analytics and Operations Christine Wilson - SVP and Head, U.S. Sales and Marketing Suma Krishnan - President, Research and Development Kate Romano - CAO Conference Call Participants Alec Stranahan - BOA Ritu Baral - TD Cowen Gavin Clark-Gartner - Evercore ISI Sami Corwin - William Blair Ry Forseth - Guggenheim Josh Schimmer - Cantor Andrea Newkirk - Goldman Sachs Operator Thank you for standing …
Read More
Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023
Read More
About Krystal Biotech, Inc. (KRYS)
- IPO Date 2017-09-20
- Website https://www.krystalbio.com
- Industry Biotechnology
- CEO Mr. Krish S. Krishnan M.B.A., M.S.
- Employees 275